Heat-Treated Lactiplantibacillus plantarum KM2 Fermentation Ameliorate Muscular Atrophy
Journal of Microbiology and Biotechnology · 2025
DOI: 10.4014/jmb.2506.06042 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Microbiology and Biotechnology, 2025. Verfasst von Minji Kang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Environmental Science and Biotechnology, Jeonju University, Jeonju 55069, Republic of Korea. Hauptthemen laut MEDLINE: Muscular Atrophy, Lactiplantibacillus plantarum, Probiotics. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Jeonju university, Korea Institute of Planning and Evaluation for Technology in Food, Agriculture and Forestry, Ministry of Agriculture, Food and Rural Affairs.
Abstract (Originalsprache)
Sarcopenia, a progressive loss of skeletal muscle mass and function, poses a significant health concern in aging populations and cancer patients. Despite ongoing pharmaceutical research, including drug repurposing strategies, no FDA-approved treatment is currently available for sarcopenia, highlighting the need for safer, food-derived interventions. This study evaluated the anti-aging and muscle-preserving effects of KLP_KM2, a postbiotic formulation derived from Lactiplantibacillus plantarum KM2, using Caenorhabditis elegans and C2C12 muscle cell models. In C. elegans, KLP_KM2 and its components significantly extended lifespan, reduced lipofuscin accumulation, enhanced pharyngeal pumping, and preserved coordinated movement patterns. These effects were accompanied by upregulation of longevity, immune/stress response, and muscle function-related genes. In C2C12 myotubes, KLP_KM2 treatment mitigated CT26-conditioned medium-induced muscle atrophy, restoring myotube diameter and length, increasing expression of myogenic markers (MyoD, myogenin, MHC I, MHC IIa), and downregulating atrophy markers (Atrogin-1, MuRF1). These findings suggest that KLP_KM2 may serve as a promising postbiotic intervention to support muscle health, prevent sarcopenia, and counteract cancer cachexia. Further in vivo mammalian studies and clinical trials are warranted to validate its therapeutic potential.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Environmental Science and Biotechnology, Jeonju University, Jeonju 55069, Republic of Korea.
- KookminBio Corporation, Seoul 02826, Republic of Korea.
- Emerging Pathogens Institute, University of Florida, Gainesville, FL 32611, USA.
- Department of Animal Sciences, Institute of Food and Agricultural Sciences, University of Florida, Gainesville, FL 32611, USA.
- Department of Food and Nutrition, Jeonju University, Jeonju 55069, Republic of Korea.
Förderung
- Jeonju university
- Korea Institute of Planning and Evaluation for Technology in Food, Agriculture and Forestry
- Ministry of Agriculture, Food and Rural Affairs
Zitieren
APA
Kang, M., Kang, M., Sung, M. H., Kim, J. H., Lee, J., Jeong, K. C., & Oh, S. (2025). Heat-Treated Lactiplantibacillus plantarum KM2 Fermentation Ameliorate Muscular Atrophy. Journal of Microbiology and Biotechnology. https://doi.org/10.4014/jmb.2506.06042
Vancouver
Kang M, Kang M, Sung MH, Kim JH, Lee J, Jeong KC, et al. Heat-Treated Lactiplantibacillus plantarum KM2 Fermentation Ameliorate Muscular Atrophy. Journal of Microbiology and Biotechnology. 2025. doi:10.4014/jmb.2506.06042
BibTeX
@article{Kang2025,
author = {Kang, Minji and Kang, Minkyoung and Sung, Moon-Hee and Kim, Jong-Hoon and Lee, Juyeon and Jeong, Kwangcheol Casey and Oh, Sangnam},
title = {Heat-Treated Lactiplantibacillus plantarum KM2 Fermentation Ameliorate Muscular Atrophy},
journal = {Journal of Microbiology and Biotechnology},
year = {2025},
doi = {10.4014/jmb.2506.06042}
}
EUVIMED